Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • Find a professional representative
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • Find a professional representative
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t180299eu1
  1. Home
  2. T 0299/18 (Concentrated liquid diet/NISSHIN OILLIO) 04-05-2022
Facebook Twitter Linkedin Email

T 0299/18 (Concentrated liquid diet/NISSHIN OILLIO) 04-05-2022

European Case Law Identifier
ECLI:EP:BA:2022:T029918.20220504
Date of decision
04 May 2022
Case number
T 0299/18
Petition for review of
-
Application number
09824548.3
IPC class
A23L 1/29
A23L 1/30
A61K 31/23
A61P 3/00
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 396.15 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

CONCENTRATED LIQUID DIET

Applicant name
The Nisshin OilliO Group, Ltd.
Opponent name
Société des Produits Nestlé S.A.
Board
3.3.09
Headnote
-
Relevant legal provisions
Rules of procedure of the Boards of Appeal Art 12(4)
European Patent Convention Art 100(a)
European Patent Convention Art 56
Keywords

Late-filed evidence - submitted with the statement of grounds of appeal

Late-filed facts - admitted (no)

"post-published" evidence taken into account - (yes)

Inventive step - unexpected improvement shown

Inventive step - (yes)

Catchword
-
Cited decisions
T 0939/92
T 1329/04
Citing decisions
-

I. This decision concerns the appeal filed by the opponent (appellant) against the opposition division's decision to reject the opposition against European patent No. 2 351 491.

II. In the notice of opposition, the opponent had requested that the patent be revoked in its entirety based on Article 100(a) EPC for lack of inventive step, among other things.

III. The documents cited during opposition proceedings included:

D1:|WO 2007/000529 A2 |

D3:|WO 2007/080149 A2 |

D6:|A. C. Bach et al., "The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy?", Journal of Lipid Research, 37, 1996, 708-726|

D7:|US 2006/0167094 Al |

D8:|J. A. Heydinger et al., "Medium chain triacylglycerols", Journal of Food Lipids, 3, 1996, 251-257 |

D9:|EP 0 843 972 A1 |

Annex I:|"Test for investigating discomfort of the upper abdomen in humans" |

The patent proprietor filed Annex I in reply to the notice of opposition.

IV. With the statement setting out the grounds of appeal, the appellant filed the following document, among other documents:

D12:|WO 2007/115282 A2|

V. With the reply to the statement setting out the grounds of appeal, the patent proprietor (respondent) filed auxiliary requests 1 to 5.

VI. Claim 1 of the patent as granted (main request) reads:

"A concentrated liquid diet having a total amount of a medium-chain fatty acid having 8 carbon atoms and a medium-chain fatty acid having 10 carbon atoms included as constitutive fatty acids of a triglyceride being 2.5 to 8.0 g per 100 kcal of the energy of the concentrated liquid diet, the concentrated liquid diet having in the total mass of the medium-chain fatty acid having 8 carbon atoms and the medium-chain fatty acid having 10 carbon atoms a rate of the medium-chain fatty acid having 10 carbon atoms being no less than 60% by mass, and a rate of the medium-chain fatty acid having 8 carbon atoms being no greater than 40% by mass."

VII. The appellant's arguments relevant to the present decision may be summarised as follows:

- D12 was feasible as the closest prior art and was to be admitted into the proceedings.

- The claimed subject-matter lacked inventive step starting from any one of D1, D3, D8 and D9 as the closest prior art. There was no evidence that a technical effect or an improvement was achieved across the scope claimed. The results in tables 2, 7 and 8 of the patent and in Annex I did not support such a conclusion. The subject-matter of the main request was obvious.

VIII. The respondent's arguments relevant to the present decision may be summarised as follows:

- D12 was not to be admitted into the proceedings.

- The claims of the main request involved an inventive step. D3 was the closest prior art. The technical problem set out in the patent, namely to provide a nutritional composition that was less likely to strain the stomach, was solved. This was demonstrated in tables 2, 7 and 8 of the patent and in Annex I.

IX. Final requests

The appellant requested that the decision under appeal be set aside and that the patent be revoked.

The respondent requested that the appeal be dismissed (main request), or alternatively that the patent be maintained on the basis of any one of auxiliary requests 1 to 5, filed with the reply to the statement setting out the grounds of appeal.

1. The patent

1.1 The patent is directed to concentrated liquid diets which comprise a large amount of medium-chain fatty acids. The diets are intended for use in the nutritional support of elderly people or hospitalised patients, for example. Medium-chain fatty acids efficiently supply energy but may induce discomfort of the upper abdomen (such as a heavy stomach feeling and irritation of the stomach) when ingested at a single time and in large amounts. The patent aims to provide a concentrated liquid diet that contains a large amount of medium-chain fatty acids and is less likely to strain the stomach (paragraphs [0002] to [0005]).

1.2 Claim 1 of the patent as granted further defines the concentrated liquid diets.

(a) The diets are rich in medium-chain fatty acids having 8 carbon atoms (i.e. C8 fatty acid) and 10 carbon atoms (i.e. C10 fatty acid), i.e. 2.5 to 8.0 g per 100 kcal.

(b) Moreover, the C10 fatty acid is no less than 60% by mass and the C8 fatty acid is no greater than 40% by mass of the total mass of C8 and C10 fatty acid. In other words, the mass ratio of C8 to C10 fatty acid is from 40:60 to 0:100.

2. Non-admission of D12

2.1 The parties disagreed as to whether D12, filed with the statement setting out the grounds of appeal, was admissible. The appellant filed it as an additional closest prior-art document and based an inventive-step objection on it.

2.2 It can be seen from the decision under appeal that the opponent did not rely on one single document as the closest prior art, but on several documents. Clearly, the opponent's view throughout the opposition proceedings was that there were more documents which represented the closest prior art. The inventive-step objections discussed in the decision involved four different documents, used as the closest prior art: D1, D3, D8 and D9. None of the inventive-step objections raised in the opposition proceedings was successful.

2.3 The opposition division maintained the patent as granted. The main request on appeal is unchanged: the respondent is still requesting that the patent be maintained as granted. Therefore, there is no change to the claims that justifies additional documents being filed.

2.4 Nevertheless, by filing D12 for the first time on appeal, the appellant sought to introduce yet another document as the closest prior art. Therefore, it presented a fresh case by raising a new inventive-step objection against the claims as granted.

2.5 The board sees no reason why the opponent, which was of the opinion that there were several documents representing the closest prior art, did not file all the documents it wished to have considered with the notice of opposition. At the least, it should have done so in the course of the opposition proceedings. There is also no explanation as to why D12 could not have been filed earlier.

2.6 Therefore, the further document that the appellant presented as the closest prior art, D12, could and should have been filed during the opposition proceedings.

2.7 For completeness, the following additional observations are made as regards the disclosure and the teaching of D12.

2.7.1 The appellant's understanding of D12 was that

- the document related to high-fat nutritional drinks comprising medium-chain triglycerides,

- the compositions disclosed had particular use in feeding the elderly, and

- all the fatty acid groups of the triglyceride could be chosen to have 10 carbon atoms.

2.7.2 However, as the respondent argued, the appellant has construed the disclosure of D12 in the manner of a mosaic, by combining several separate embodiments and selecting the passages that suited its purpose from the entire disclosure.

2.7.3 In more detail, claim 1 of D12 is directed to a nutritional drink that provides specified physiological levels of beta-hydroxybutyrate and comprises, among other specified ingredients, medium-chain triglycerides with fatty acids having 5 to 12 carbons atoms. The aim of D12 is to treat or prevent cognitive impairment, not to overcome discomfort of the upper abdomen or strain on the stomach. D12 exemplifies a wide range of dosage forms and concentrations for the medium-chain triglycerides (example 2). The fatty acids may or may not include fatty acids with 10 carbon atoms. For instance, it may include only fatty acids with 6 carbon atoms. No preference is indicated (paragraphs [0046] and [0047]).

2.7.4 Therefore, the disclosure in D12 is not exclusively directed to high-fat nutritional drinks comprising medium-chain triglycerides in which all the fatty acid groups of the triglyceride have 10 carbon atoms. In this respect, D12 is not a more promising springboard than D3.

2.8 To conclude, D12 is not admitted into the appeal proceedings (Article 12(4) RPBA 2007).

3. Main request - inventive step

3.1 The appellant contested the opposition division's decision on inventive step. In its view, claim 1 as granted and dependent claims 2 to 4 lacked inventive step.

3.2 Selection of the closest prior art

3.2.1 The appellant argued, as in the decision under appeal, that any one of D1, D3, D8 and D9 could be used as the closest prior art.

3.2.2 The board agrees with the opposition division and the respondent that D3 is the closest prior art. D3 relates to methods and compositions for providing nutrition rich in lipids to stressed or critically ill patients (paragraphs [0001], [0015] and [0020]). This purpose is similar to that of the patent.

3.2.3 The board explained in its communication under Article 15(1) RPBA 2020 that none of D1, D8 and D9 related to a concentrated liquid and consequently did not qualify as the closest prior art. In particular:

- D1 related to the treatment of keratinous dryness,

- D8 was a scientific publication on medium-chain triacylglycerols, their nutritional benefits and their use in various food applications, and

- D9 related to the treatment of metabolic syndrome, in particular to a food composition beneficial in lowering lipid levels in blood plasma, and was not a more promising springboard than D3.

3.2.4 The board has no reason to revisit this assessment because the appellant has not provided any counter-arguments in this regard.

3.3 The distinguishing feature(s)

3.3.1 Paragraph [0055] of the closest prior art, D3, discloses the composition Peptamen**(®) 1.5, which comprises:

- an energy density of 1.5 kcal/ml,

- a protein source which provides 18% of total energy, and

- a lipid source which contains 70% medium-chain triglycerides, i.e. fractionated coconut oil and palm kernel oil, and 30% long-chain triglycerides.

3.3.2 It is uncontested that a distinguishing feature of claim 1 is that the concentrated liquid diet has a ratio of C10 fatty acid of no less than 60% by mass and a ratio of C8 fatty acid of no greater than 40% by mass in the total mass of C8 and C10 fatty acid. In other words, D3 does not disclose feature (b) identified in point 1.2 above.

3.3.3 With regard to feature (a) identified in point 1.2 above, in view of the board's conclusion on inventive step set out below, it is not necessary to decide whether this feature is a further distinguishing feature of claim 1.

3.4 What is the technical problem?

3.4.1 In paragraph [0005], the patent addresses the problem of providing a concentrated liquid diet that contains a large amount of medium-chain fatty acid and is less likely to strain the stomach.

3.4.2 In the decision under appeal, the opposition division examined the experimental results in tables 2, 7 and 8 of the patent and in Annex I. It then concluded (in point 3.3.3) that

"the objective as posed in the patent specification of providing a concentrated liquid diet to reduce stomach strain is plausibly achieved across the whole of the scope claimed of the patent as granted".

3.4.3 The appellant argued that the results in tables 2, 7 and 8 of the patent and in Annex I did not support the conclusion that the problem was solved across the whole of the scope claimed.

3.4.4 The contested evidence supporting a technical effect is discussed in points 3.5 to 3.7 and the conclusions are drawn in point 3.8, as all set out below.

3.5 Results in table 2 of the patent

3.5.1 Table 2 shows the results of experiments in which compositions are fed to rats and the effects on the gastric mucosa are analysed. Two types of composition are compared:

- On the one hand, three compositions (reference examples 1 to 3) are examined. They comprise a ratio of n-octanoic acid (a C8 fatty acid) to n-decanoic acid (a C10 fatty acid) of 40:60, 20:80 and 0:100, respectively. The three compositions have the ratio of medium-chain fatty acid called for in claim 1, i.e. they are compositions representing the invention.

- On the other hand, a comparative composition is examined which comprises a ratio of n-octanoic acid to n-decanoic acid of 60:40. This composition does not fall under claim 1.

3.5.2 The compositions representing the invention are found to cause a lower number of areas of patchy redness in the rats' gastric mucosa. The results are described as being significantly different as compared with the results of the comparative composition.

3.5.3 The appellant argued that these results were irrelevant because they did not demonstrate an effect on humans. However, it provided no evidence that the analysis of the rats' gastric mucosa is from a scientific viewpoint unsuitable for demonstrating how the compositions representing the invention behave in the human body.

3.5.4 Therefore, it can be acknowledged that

- the number of areas of patchy redness in the rats' gastric mucosa is an indicator of stomach strain and

- the results in table 2 would be expected to be observed on humans ingesting the compositions.

3.5.5 The board also agrees with the respondent that the morphological/cellular response shown in table 2 indicates discomfort in a subject, regardless of whether the subject is a human or a rat.

3.5.6 On the basis of the results in table 2 alone, it is credible that the compositions in claim 1 are less likely to strain the stomach.

3.6 Results in tables 7 and 8 of the patent

3.6.1 The patent sets out further experiments in which human panellists assess discomfort in the upper abdomen after ingesting several compositions. The panellists assign a value to individual evaluation items (e.g. feeling irritation in the upper abdomen, getting nausea, belching); the higher the value, the higher the level of discomfort.

Tables 7 and 8 set out, for each composition,

(i) the sum of values the panellists assigned to each individual evaluation item, and

(ii) a total score, which is the total sum of the values the panellists assigned.

The compositions tested correspond to those identified in point 3.5.1 above (reference examples 1 to 3 and the comparative composition). The compositions in tables 7 have a concentration of medium-chain fatty acid of 2.8 g per 100 kcal of the energy of the concentrated liquid diet. The compositions in table 8 have a higher concentration of medium-chain fatty acid, 5.6 g per 100 kcal.

3.6.2 The compositions representing the invention are generally found to have a lower score; in other words, they cause less discomfort.

3.6.3 The appellant's view was that these results did not support the conclusion that the problem set out in the patent was solved across the whole of the scope claimed. It made the following arguments.

- The number of panellists was small and their assessment was subjective.

- The results in tables 7 and 8 did not show a statistically significant difference for all the compositions representing the invention. This in particular concerned the compositions having a mass ratio of C8 to C10 fatty acid of 40:60 or 20:80.

- The changes in values for individual evaluation items did not correlate with changes in mass ratio of C8 to C10 fatty acid. It was not possible to determine from the data in tables 7 and 8 which evaluation item may be improved for any diet falling within the scope of claim 1.

- The experiments in tables 7 and 8 were carried out with octanoic acid and decanoic acid, but there was no evidence that the results were achievable with any C8 and C10 fatty acid.

3.6.4 However, the appellant's arguments are not convincing.

3.6.5 There is no indication that the number of panellists is unsuitable for the purpose of demonstrating the effect of the invention. Furthermore, it is unavoidable that discomfort in the upper abdomen is assessed according to subjective evaluations, which may not be as repeatable or reproducible as data obtained from measuring an invariable sample.

3.6.6 Nevertheless, as the respondent argued, it is conclusive that a human panellist may experience an overall reduction in discomfort due to subtle influences from each of the evaluation items and that this is reflected in the total score. In view of this, it is justified that the total score be given more weight than the assessment of the individual evaluation items. In this context, it is observed that the aim of the patent is not to address specific aspects such as reducing nausea or belching.

3.6.7 Furthermore, the results in tables 7 and 8 may not show a statistically significant difference that stands up to strict, mathematical scrutiny of the data. Nevertheless, they show a clear trend to the naked eye. The trend which is derivable when evaluating the total score in tables 7 and 8 does not contradict the results in table 2. On the contrary, taken together, these results additionally support the conclusion reached based on the tests shown in table 2, namely that all the compositions representing the invention cause less discomfort, i.e. less stomach strain, than the comparative composition.

3.6.8 The appellant's speculative argument that the results in tables 7 and 8 may not be obtained for any C8 or C10 fatty acid is based on abstract considerations and is not convincing either. Claim 1 relates to a concentrated liquid diet which comprises C8 and C10 fatty acid and defines an amount of it (2.5 to 8.0 g per 100 kcal). A skilled reader of claim 1 would immediately think of octanoic acid and decanoic acid in this context. Moreover, the appellant has not explained what C8 and C10 substances that comply with the definition of claim 1 it had in mind when it presented its argument.

3.6.9 To conclude, the results in tables 7 and 8 further support the conclusion that the compositions in claim 1 are less likely to strain the stomach.

3.7 Annex I

3.7.1 The patent proprietor filed Annex I in reply to the notice of opposition. These tests are similar to those in tables 7 and 8; however, the compositions representing the invention comprise a mass ratio of n-octanoic acid to n-decanoic acid of 30:70 and C8 and C10 fatty acid at 7.4 g per 100 kcal of the energy of the concentrated liquid diet.

3.7.2 As in the results in tables 7 and 8, the compositions representing the invention are generally found to have a lower score (i.e. they cause less discomfort) and to have a total score that is significantly different (P < 0.05) as compared with the comparative composition.

3.7.3 Here, the appellant's criticism was that:

- according to established case law (T 939/92 and T 1329/04) "post-published" evidence could not be used to demonstrate a technical effect that was not made "plausible" in the application as filed, and

- the tests were carried out with a mass ratio of n-octanoic acid to n-decanoic acid of 30:70, which had not been exemplified in the patent.

3.7.4 However, these arguments failed to convince the board.

3.7.5 As explained above in points 3.5 and 3.6, the patent as well as the application as filed include sufficient evidence supporting the conclusion that the compositions in claim 1 solve the problem set out in the patent, namely to reduce stomach strain. In view of this, the proof of the effect does not reside exclusively in "post-published" evidence, i.e. Annex I filed after the date of filing and not publicly available prior to that date. The effect is already credible based on the application as filed.

3.7.6 In T 939/92 the competent board's reasoning was that, as no evidence had been submitted in order to demonstrate a certain effect, the latter could not be taken into account (Reasons for the Decision, point 2.6.4). Therefore, this decision does not support the appellant's view that evidence filed after the date of filing, such as Annex I in the present case, should not be considered.

3.7.7 T 1329/04 concerns a specific situation in which, in view of the common general knowledge, there were serious doubts as to whether the problem was credibly solved. The supporting evidence provided in that case, filed after the date of filing and not publicly available prior to that date, was the first disclosure going beyond speculation (Reasons for the Decision, point 12). The present case is different. Given the disclosure in the application as filed, the board cannot identify such serious doubts.

3.7.8 The appellant argued that compositions with a mass ratio of n-octanoic acid to n-decanoic acid of 30:70 were not exemplified in the patent. Therefore, Annex I was not relevant.

3.7.9 The opposite is true. First, the compositions examined in Annex I fall under claim 1. Second, they include a mass ratio of C8 fatty acid of 30%. This is close to the end point of the mass ratio of C8 to C10 fatty acid of 40:60, which the appellant regarded as critical (see point 3.6.3 above). Third, the C8 and C10 fatty acid is in the composition at 7.4 g per 100 kcal, which means at a concentration towards the upper end of the range called for in claim 1. Therefore, the results in Annex I fill a (potential) gap in terms of the evidence provided. They further endorse the conclusion that reducing stomach strain is achieved across the whole of the scope claimed.

3.7.10 For the sake of completeness, the board observes that in Annex I the total score of the compositions representing the invention is significantly different (P < 0.05) as compared with the comparative composition. Nevertheless, in the context of the present case, strict statistical considerations are not considered to be decisive when assessing the corroborative value of the evidence (see point 3.6.7 above).

3.7.11 To conclude, Annex I additionally confirms the results given in tables 2, 7 and 8 of the patent.

3.8 Concluding remarks on the evidence

3.8.1 As explained above in points 3.5 and 3.6, the patent includes evidence supporting the conclusion that the compositions in claim 1 reduce stomach strain. This is further corroborated by the results in Annex I. There is also no verifiable evidence demonstrating that the effect might not be achieved across the whole of the scope claimed.

3.8.2 In particular, the appellant has not prepared its own tests which would support its position. Its objections were restricted to criticising, presenting allegations and attempting to raise doubts based on the patent proprietor's experimental results.

3.8.3 Therefore, on the basis of the evidence before the board, it can be concluded that the compositions in claim 1 reduce stomach strain.

3.9 Formulation of the technical problem

The technical problem identified in the patent (see point 3.5.1 above) and acknowledged by the opposition division (see point 3.5.2) need not be reworded.

3.10 Obviousness

3.10.1 There is no suggestion in the cited prior art of solving the technical problem by modifying the mass ratio of C10 and C8 fatty acid as set out in claim 1.

3.10.2 In particular, as already explained in the opposition division's decision, neither D6 nor D7 is concerned with the same problem or provides an incentive to modify the mass ratio of C8 to C10. The subject-matter of claim 1 is not obvious over D3 either alone or in combination with D6 or D7.

3.10.3 The same reasoning applies to D1, D8 and D9. None of these documents relates to the problem of providing a concentrated liquid diet which reduces discomfort of the upper abdomen. Their disclosure would not have motivated the skilled person to modify the mass ratio of C8 to C10 fatty acid.

3.11 Therefore, the subject-matter of claim 1, and also of dependent claims 2 to 4, involves an inventive step. The ground for opposition under Article 100(a) EPC in conjunction with Article 56 EPC does not prejudice the maintenance of the patent as granted.

Order

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility